A first-of-its-kind vaccine, termed AST-VAC2, has moved into a Phase I clinical trial for non-small cell lung cancer patients.
Browsing: Disease Area > Lung
A preliminary report has revealed that a blood test could be used as a tool to detect early-stage lung cancer in patients.
Roche has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® plus chemotherapy helped individuals with metastatic non-squamous NSCLC, who lived significantly longer compared with those who received chemotherapy alone
Discover the case of nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer in this article from the impactful journal Immunotherapy.
Researchers have devised a method that allows them to personalize the lung cancer screening decision for every patient; the tool is termed Lung Decision Precision.
AstraZeneca and MedImmune have announced results of their Phase III PACIFIC trial.
Keytruda® has significantly improved overall survival and progression-free survival as a first-line treatment for squamous non-small cell lung cancer in the Phase III KEYNOTE-407 trial.
In this patient perspective find out T.J.’s viewpoint on the potentially practice-changing lung cancer findings presented at the AACR 2018.
This world-first-treatment could potentially offer hope to lung cancer patients with previously untreatable lung tumors.
AstraZeneca (DE, USA) and Medimmune (MD, USA), recently announced results from the ARCTIC trial in third-line non-small cell lung cancer (NSCLC).